Purpose By 2050 it is projected that 115 million people worldwide will have Alzheimer's
Disease (AD)[1]. Recent attempts have been made to redefine the diagnostic criteria of AD …

PET based tools can improve the early diagnosis of Alzheimer's disease (AD) and
differential diagnosis of dementia. The importance of identifying individuals at risk of …

Background: Amyloid PET (aPET) imaging could improve patient outcomes in clinical
practice, but the extent of impact needs quantification. Objective: To provide an aggregated …

Use of biomarkers in the detection of early and preclinical Alzheimer's disease (AD) has
become of central importance following publication of the NIA-Alzheimer's Association …

AD is a progressive and irreversible neurodegenerative disorder clinically characterized by
memory loss and cognitive decline that severely affect the activities of daily living. 1 AD is …

Objectives The aim of this article was to review the current role of brain PET in the diagnosis
of Alzheimer dementia. The characteristic patterns of glucose metabolism on brain FDG-PET …

Preclinical diagnosis of Alzheimer's disease (AD) is one of the major challenges for the
prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic …

PURPOSE: To assess the operating characteristics of positron emission tomography (PET)
by using fluorine 18 fluorodeoxyglucose (FDG) in the diagnosis of Alzheimer disease …

Imaging or tissue biomarker evidence has been introduced into the core diagnostic pathway
for Alzheimer's disease (AD). PET using 18 F-labelled beta-amyloid PET tracers has shown …

The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit
from biomarkers that are sensitive to subtle brain changes occurring prior to the onset of …